ZLAB (Zai Lab) Retained Earnings : $-2,371.4 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Zai Lab Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Zai Lab's retained earnings for the quarter that ended in Sep. 2024 was $-2,371.4 Mil.

Zai Lab's quarterly retained earnings declined from Mar. 2024 ($-2,249.5 Mil) to Jun. 2024 ($-2,329.7 Mil) and declined from Jun. 2024 ($-2,329.7 Mil) to Sep. 2024 ($-2,371.4 Mil).

Zai Lab's annual retained earnings declined from Dec. 2021 ($-1,418.1 Mil) to Dec. 2022 ($-1,861.4 Mil) and declined from Dec. 2022 ($-1,861.4 Mil) to Dec. 2023 ($-2,196.0 Mil).

Zai Lab Retained Earnings Historical Data

The historical data trend for Zai Lab's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Retained Earnings Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-444.70

-713.60

-1,418.07

-1,861.36

-2,195.98

Zai Lab Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Retained Earnings	Get a 7-Day Free Trial															-2,100.55	-2,195.98	-2,249.45	-2,329.73	-2,371.40

Zai Lab Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Zai Lab (NAS:ZLAB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Zai Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

ZLAB:Mexico 09688:Hong Kong 1ZLB:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Executives

Yajing Chen	officer: Chief Financial Officer	314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142
Richard Gaynor	director	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Edmondson Frazor Titus Iii	officer: Chief Legal Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Joshua L Smiley	officer: Chief Operating Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Rafael Amado	officer: See Remarks	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ying Du	director, officer: Chairwoman & CEO	C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210
Harald Reinhart	officer: Chief Medical Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Peter Wirth	director	37 HANCOCK STREET, BOSTON MA 02114
John D Diekman	director	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Tao Fu	director, officer: President & COO	3175 HANOVER STREET, PALO ALTO CA 94304
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Cho William Ki Chul	officer: Chief Financial Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Kai-xian Chen	director	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210